Belgium’s largest drugmaker UCB on Friday announced the successful closing of the sale, divestment and license of its mature ...

For patients with axial spondyloarthritis (axSpA) who experience extra musculoskeletal symptoms such as acute anterior uveitis, bimekizumab (BKZ) may offer protective benefits, according to study ...

The U.S. Food and Drug Administration has approved UCB's Bimzelx (bimekizumab-bkzx) for the treatment of adults with moderate ...

The Food and Drug Administration (FDA) has approved Bimzelx ® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults.

周五，BTIG将Protagonist Therapeutics (NASDAQ:PTGX)的目标价从51.00美元上调至67.00美元，同时维持对该股的中性评级。分析师强调了Protagonist的PN-881（一种口服IL-17A/F抑制剂）的潜力，该药物在临床前试验中显示出与bimekizumab相当的效力，这促使了此次调整。

MoonLake Immunotherapeutics' shares have dipped recently, with a catalyst vacuum until mid-2025 when pivotal trial data for ...

The novel IL-17A and IL-17F inhibitor has been approved for moderate to severe hidradenitis suppurativa, a chronic and ...

▎药明康德内容团队编辑优时比（UCB）今天宣布，美国FDA已批准Bimzelx（bimekizumab）用于治疗中度至重度化脓性汗腺炎（HS）成人患者。根据新闻稿，Bimzelx是可同时选择性抑制白介素17A（IL-17A）和白介素17F（IL-17 ...

Having absorbed other study stumbles in the past few months, the company now has halted development of dalzanemdor in treating Huntington’s disease after top-line phase II data showed it missed a ...

The FDA has approved UCB's Bimzelx for moderate-to-severe hidradenitis suppurativa, offering a new treatment option for this ...

The US Food and Drug Administration has approved bimekizumab, a humanized interleukin (IL)-17A and IL-17F antagonist, for the ...

FDA approves UCB's Bimzelx for adults with moderate to severe hidradenitis suppurativa, supported by Phase 3 trials showing significant symptom improvement.